Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Journal Article (Clinical Trial;Journal Article)
RO4929097 is a potent and selective inhibitor of γ-secretase and as a result is able to inhibit Notch pathway signaling. The activity of RO4929097 was evaluated against the in vivo panels of the Pediatric Preclinical Testing Program (PPTP). RO4929097 induced significant differences in event-free survival (EFS) distribution compared to control in 6 of 26 (23%) of the evaluable solid tumor xenografts and in 0 of 8 (0%) of the evaluable ALL xenografts. The most consistent tumor growth delay effects were noted in the osteosarcoma panel. RO4929097 at the dose and schedule evaluated demonstrated little antitumor activity against childhood cancer xenografts.
Full Text
Duke Authors
Cited Authors
- Kolb, EA; Gorlick, R; Keir, ST; Maris, JM; Lock, R; Carol, H; Kurmasheva, RT; Reynolds, CP; Kang, MH; Wu, J; Houghton, PJ; Smith, MA
Published Date
- May 2012
Published In
Volume / Issue
- 58 / 5
Start / End Page
- 815 - 818
PubMed ID
- 22052798
Pubmed Central ID
- PMC3276746
Electronic International Standard Serial Number (EISSN)
- 1545-5017
Digital Object Identifier (DOI)
- 10.1002/pbc.23290
Language
- eng
Conference Location
- United States